HAYA Therapeutics Launches First Human Trial of RNA-Targeting Heart Failure Drug

Heart failure and cardiac fibrosis represent a major frontier in longevity medicine. Stiffening of the heart muscle due to excess scar tissue — fibrosis — is a key driver of diastolic dysfunction, reduced exercise capacity, and premature cardiovascular death. Despite decades of research, no therapy directly reverses cardiac fibrosis at the molecular level, making this trial a notable milestone.

HAYA Therapeutics has enrolled and dosed the first cohort in a Phase 1a/b trial of HTX-001, an antisense oligonucleotide that targets the WISPER long non-coding RNA. Long non-coding RNAs are genetic regulators that don't code for proteins but powerfully influence cell behavior. WISPER specifically promotes cardiac myofibroblasts — the fibrosis-driving cells — to maintain a scarring state. By silencing WISPER, HTX-001 aims to reprogram these cells away from a fibrotic phenotype, potentially softening and partially reversing existing scar tissue.

Preclinical data cited by the company showed reductions in pathological cardiac fibrosis and measurable improvements in heart function, though these results have not yet been peer-reviewed or published in a major journal. The trial's first phase focuses on safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, before advancing to patients with nonobstructive hypertrophic cardiomyopathy — a condition estimated to affect 30 to 60 percent of all hypertrophic cardiomyopathy patients and characterized by marked fibrosis and impaired diastolic filling.

For longevity-focused individuals, cardiac fibrosis is increasingly recognized as a modifiable aging biomarker. Reducing fibrotic burden could translate into better heart function, improved exercise tolerance, and lower cardiovascular mortality across the lifespan.

Important caveats apply. HTX-001 is not approved by the FDA, EMA, or any regulatory body. Phase 1 trials primarily assess safety, not efficacy. Preclinical promise frequently does not translate to human benefit, and years of further study will be required before any clinical application.